Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2023-06-20

FDA Approved: SYNJARDY XR — Supplemental Application (Boehringer Ingelheim Pharmaceuticals, Inc.)

View source ↗

Summary

The FDA approved a supplemental application for SYNJARDY XR (empagliflozin/metformin hydrochloride) by Boehringer Ingelheim Pharmaceuticals, Inc.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • SYNJARDY XR (Empagliflozin, Metformin hydrochloride)

Snippet

SUPPL AP for SYNJARDY XR (EMPAGLIFLOZIN, METFORMIN HYDROCHLORIDE)